Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Dravet Syndrome
Interventions: ION337; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina + 3 more

Conditions: Healthy Participants
Interventions: LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium; Biological · Drug · Procedure + 1 more
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Pancreatic Adenocarcinoma
Interventions: Pimasertib, Gemcitabine, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Pancreatic Cancer
Interventions: GVAX pancreatic cancer vaccine; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions: VT30; Drug
Lead sponsor: Venthera, Inc., a BridgeBio company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Nutritional Deficiency
Interventions: Study 1: Whey Supplement Day 1, Study 1: Whey Supplement Day 2, Study 2: Whey Supplement; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 3 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Overweight, Obese
Interventions: Steps to Health, Steps to Health Plus!; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: Matching placebo, Cenerimod; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Anniston, Alabama • Clearwater, Florida

Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions: ATTO-1310, ATTO-1310 Placebo; Drug
Lead sponsor: Attovia Therapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Encinitas, California • Rocklin, California • Sacramento, California + 7 more

Conditions: Squamous-Cell Non-Small-Cell Lung Cancer
Interventions: Bemarituzumab, Docetaxel, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Orange, California • Morristown, New Jersey • The Bronx, New York + 1 more

Conditions: Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Augusta, Georgia + 9 more

Conditions: Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
Interventions: Ibrutinib, Durvalumab; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more

Conditions: Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Interventions: eFT508, Avelumab; Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more

Conditions: Neoplasms
Interventions: JNJ-63723283; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Stress
Interventions: Art Pedagogy and Mindfulness; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glycemic Response, Breast Feeding, Exclusive, Eating Behavior
Interventions: Beef Diet Intervention, Impossible Beef Diet Intervention; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced Solid Tumor
Interventions: M6620, Gemcitabine, Cisplatin, Etoposide, Carboplatin, Irinotecan; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 24
States / cities: Phoenix, Arizona • San Diego, California • Stanford, California + 21 more

Conditions: Post-Traumatic Stress Disorder, Overweight and Obesity, Metabolic Syndrome, Inflammation
Interventions: Mediterranean Diet & Physical Activity, Usual Care; Behavioral
Lead sponsor: Stony Brook University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Commack, New York

Conditions: Hepatitis C
Interventions: Eltrombopag, Antiviral therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 47
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more

Conditions: Vagus Nerve Stimulation
Interventions: Multi-Electrode Array (MEA) Recording; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Partial Oncolysis, SV-102; Procedure · Drug
Lead sponsor: Syncromune, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 23
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 19 more

Conditions: Advanced Solid Tumors, Pharmacokinetics of 14C-OSI-906
Interventions: radio-labeled OSI-906, OSI-906; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Tacoma, Washington

Search by objective public record fields.

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

A Study of LY2940680 in Healthy Participants

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Bioavailability of Zinc and Iron From a Whey-based Protein Supplement Consumed With a Habitual Plant-based Diet

Steps to Health: Targeting Obesity in the Health Care Workplace

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Being Present With Art: The Impact of Mindful Engagement With Art on Awareness and Connection

Study of Nutrition in Postpartum and Early Life Feeding Study

M6620 First in Human Study

Lifestyle Intervention to Reduce Body Weight and Systemic Inflammation Among World Trade Center Responders

Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Recording Cutaneous Vagal Nerve Activity With Multi-Electrode Array (MEA) in Patients Undergoing VNS Therapy

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body